Madam Speaker, I appreciated having the opportunity to listen to the member. I have been on the industry committee so we have had a lot of discussions about when the vaccines would arrive, the efficacy of them and the difference as far as the time frame from 21 or 28 days up to the four months.
The member mentioned quite a bit about what took place in the United Kingdom, that being the other country where we have seen the off-label use. That debate rages on there as well.
I wonder if the member could discuss some of the other countries and why they have chosen to stay with the 21 and 28 days.